Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck is constructing a $1 billion drug manufacturing facility in Wilmington, Delaware, as part of its commitment to investment and growth in the United States. The company on Tuesday said it ...